Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of “Moderate Buy” from Analysts

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $44.25.

Several research firms have commented on COLL. Truist Financial upped their price objective on Collegium Pharmaceutical from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Zacks Research lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a report on Tuesday, October 28th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Collegium Pharmaceutical in a research report on Tuesday. Finally, HC Wainwright increased their target price on shares of Collegium Pharmaceutical from $44.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, November 7th.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Thomas B. Smith sold 17,478 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $38.42, for a total value of $671,504.76. Following the completion of the sale, the executive vice president directly owned 70,264 shares in the company, valued at $2,699,542.88. The trade was a 19.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Colleen Tupper sold 30,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $40.53, for a total value of $1,215,900.00. Following the transaction, the chief financial officer owned 126,667 shares in the company, valued at $5,133,813.51. This trade represents a 19.15% decrease in their position. The disclosure for this sale is available in the SEC filing. 2.51% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Illinois Municipal Retirement Fund boosted its holdings in Collegium Pharmaceutical by 1.6% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 17,281 shares of the specialty pharmaceutical company’s stock worth $605,000 after buying an additional 278 shares during the last quarter. Vident Advisory LLC lifted its position in shares of Collegium Pharmaceutical by 1.9% in the third quarter. Vident Advisory LLC now owns 15,466 shares of the specialty pharmaceutical company’s stock valued at $541,000 after acquiring an additional 281 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Collegium Pharmaceutical by 67.0% in the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock worth $31,000 after acquiring an additional 350 shares during the last quarter. Assetmark Inc. increased its position in shares of Collegium Pharmaceutical by 8.4% during the third quarter. Assetmark Inc. now owns 4,551 shares of the specialty pharmaceutical company’s stock worth $159,000 after purchasing an additional 352 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Collegium Pharmaceutical by 1.4% during the second quarter. Franklin Resources Inc. now owns 29,172 shares of the specialty pharmaceutical company’s stock worth $863,000 after purchasing an additional 409 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL traded up $1.19 during midday trading on Friday, reaching $45.14. The company’s stock had a trading volume of 365,481 shares, compared to its average volume of 529,884. The company has a quick ratio of 1.27, a current ratio of 1.36 and a debt-to-equity ratio of 2.71. The stock has a fifty day moving average of $37.05 and a 200 day moving average of $34.02. Collegium Pharmaceutical has a twelve month low of $23.23 and a twelve month high of $48.18. The firm has a market capitalization of $1.43 billion, a PE ratio of 28.04 and a beta of 0.61.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, September 4th. The specialty pharmaceutical company reported $1.26 earnings per share for the quarter. The company had revenue of $135.55 million for the quarter. Collegium Pharmaceutical had a return on equity of 102.03% and a net margin of 7.72%. On average, equities analysts expect that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.